femoston 1 mg, 10 m milligram film coated tablet
bgp products ltd - estradiol hemihydrate, dydrogesterone - film coated tablet - 1 mg, 10 m milligram - progestogens and estrogens, sequential preparations
femoston-conti 0.5/2.5 milligram film coated tablet
bgp products ltd - estradiol, dydrogesterone - film coated tablet - 0.5/2.5 milligram - progestogens and estrogens, fixed combinations
femurest-conti 1/5 milligram film coated tablet
bgp products ltd - estradiol hemihydrate, dydrogesterone - film coated tablet - 1/5 milligram - progestogens and estrogens, fixed combinations
influvac sub-unit 0.5 microgram suspension for injection
bgp products ltd - a/california/7/2009 (h1n1)pdm09-like strain (a/california/7/2009, x-181), a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b), b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 0.5 microgram - influenza vaccines
lipantil micro 200 milligram capsules hard
bgp products ltd - fenofibrate - capsules hard - 200 milligram - fibrates
lipantil supra 215 milligram film coated tablet
bgp products ltd - fenofibrate - film coated tablet - 215 milligram - fibrates
colofac 135 milligram tablets
bgp products ltd - mebeverine hydrochloride - tablets - 135 milligram - synthetic anticholinergics, esters with tertiary amino group - synthetic anticholinergics, esters with tertiary amino group - for use in the management of irritable bowel syndrome, (particularly gastrointestinal spasm).
femoston 2 mg, 10 m milligram film coated tablet
bgp products ltd - estradiol hemihydrate, dydrogesterone - film coated tablet - 2 mg, 10 m milligram - progestogens and estrogens, sequential preparations - sequential hormone replacement therapy - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women at least 6 months since the last menses. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.
lactecon 3.335 g/5ml oral solution
bgp products ltd - lactulose - oral solution - 3.335 g/5ml - osmotically acting laxatives
dilantin-125 suspension
bgp pharma ulc - phenytoin - suspension - 125mg - phenytoin 125mg - hydantoins